Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2002

View Archived Issues

Novel COX-2 inhibitors in early development at GSK

Tachykinin antagonists for use in depression and other disorders

Synthesis of novel 5-HT2A receptor ligands reported at Medicinal Chemistry Symposium

Abbott identifies aryl tetrahydropyridine farnesyltransferase inhibitors

Biological activity of paclitaxel-glucose conjugate tested in human cancer cell lines

Discovery of CCR3 receptor antagonists with potential in allergic asthma

Novel antiinflammatory agents from Celgene act by inhibiting transcriptional activation in T-cells

A wealth of data on lumiracoxib presented at the EULAR congress

NN-2211 may be useful for treating obesity and type 2 diabetes

Preclinical findings reported for aldose reductase inhibitor fidarestat

New data on ragaglitazar discussed at the ADA scientific sessions

Lead PTP1B inhibitor with blood glucose-lowering effects identified by Korean group

Hydroxamate-based antibiotics targeting LpxC in Gram-negative bacteria

DISC-GMCSF completes phase I study

NDA filing for Purdue's abuse-resistant pain medication delayed

FSME-IMMUN vaccine approved for adult use in Germany

Chiron grants nonexclusive HCV license to Merck & Co.

Argenta Discovery and Amedis enter drug discovery collaboration

Immtech's lead hepatitis C compounds to be validated for further development

Trospium completes phase III trial in overactive bladder

CoFactor phase II trial design finalized

Asthma drug candidate selected under Texas Biotechnology/Schering-Plough collaboration

Frova launched in U.S.

Human 5-HT2C receptor ligands selected for further evaluation at Vernalis for use in obesity

Sankyo patents new antitumor compounds

3-Dimensional presents new trypsin-like protease inhibitors in recent patent

Potent inhibitors of IL-12 production and potential therapeutic applications

Mast cell stabilizers synthesized at Alcon active in model of allergic conjunctivitis